Investment Opportunities

Why Invest in MEDomics^TM?

NextGen-based sequencing is rapidly advancing and will revolutionize personalized medicine. MEDomics^TM is a CLIA laboratory focused on applying NextGen sequencing technology to molecular diagnosis. The breadth and depth of NextGen diagnostic expertise at MEDomics^TM is unique. We “live and breathe” NextGen sequencing – a critical advantage in this fast moving field. In our opinion, the opportunities generated by $1 of investment in this field today may require $10 of investment in 3 years from now.

The competitive advantages that MEDomics^TM encompasses (please find partial list below), outlines why an investment in us may be attractive.

• Major first mover advantages that are difficult to duplicate

• Functioning, integrated, and tested team with an unrivaled track record for bringing novel molecular diagnostics to market

• Enhanced trade secrets and intellectual property pipeline

Please contact us to inquire about investment and joint venture opportunities

(President/Founder: Steve.Sommer@medomics.com)